20 February 2024 in International Journal of Colorectal Disease
Purpose: Transanal total mesorectal excision (taTME) was developed to provide better vision during resection of the mesorectum. Conflicting results have shown an increase in local recurrence and shorter survival after taTME. This study compared the outcomes of taTME and abdominal (open, laparoscopic, robotic) total mesorectal excision (abTME). Methods: Patients who underwent taTME or abTME for stages I–III rectal cancer and who received an anastomosis were included. A retrospective analysis of a prospectively conducted database was performed. The primary endpoints were overall survival (OS), cancer-specific survival (CSS), and disease-free survival (DFS). Risk factors were adjusted by propensity score matching (PSM). The secondary endpoints were local recurrence rates and combined poor pathological outcomes. Results: From 2012 to 2020, a total of 189 patients underwent taTME, and 119 underwent abTME; patients were followed up for a mean of 54.7 (SD 24.2) and 78.4 (SD 34.8) months, respectively (p < 0.001). The 5-year survival rates after taTME and abTME were not significantly different after PSM: OS: 78.2% vs. 88.6% (p = 0.073), CSS: 87.4% vs. 92.1% (p = 0.359), and DFS: 69.3% vs. 80.9% (p = 0.104), respectively. No difference in the local recurrence rate was observed (taTME, n = 10 (5.3%); abTME, n = 10 (8.4%); p = 0.280). Combined poor pathological outcomes were more frequent after abTME (n = 36, 34.3%) than after taTME (n = 35, 19.6%) (p = 0.006); this difference was nonsignificant according to multivariate analysis (p = 0.404). Conclusion: taTME seems to be a good treatment option for patients with rectal cancer and is unlikely to significantly affect local recurrence or survival. However, further investigations concerning the latter are warranted. Trial registration: ClinicalTrials.gov (NCT0496910).
6 March 2026 in Techniques in Coloproctology
Background The International Study Group of Rectal Cancer (ISREC) provides a classification of anastomotic leakage (AL). This classification categorises the severity of AL according to its clinical management. The aim of this study was to determine whether AL and its management influence survival. Methods Patients who underwent elective mesorectal excision (PME or TME) for primary rectal cancer stages I–III and who underwent anastomosis were included. A retrospective analysis of clinical data retrieved from a prospectively conducted database was performed. The primary endpoint was cancer-specific survival (CSS). Risk factors were adjusted by propensity score matching (PSM). The secondary endpoints were overall survival (OS), disease-free survival (DFS), and local recurrence-free rate (RFR). Results A total of 942 patients underwent surgery between 1991 and 2020 and were followed for a mean of 71.9 (SD 48.5) months. AL occurred in 141 patients (15.0%). Twenty-three patients had grade A AL (16.3%), 48 patients had grade B AL (34.0%), and 70 patients had grade C AL (49.6%). AL had no significant negative influence on the 5-year propensity score-adjusted survival rate for CSS (no AL 92.2%, AL 87.9%, p = 0.161), but did so on OS (no AL 78.6%, AL 66.9%, p = 0.005), DFS (no AL 72.9%, AL 60.9%, p = 0.011), and RFR (no AL 94.2%, AL 88.5%, p = 0.047). The severity of AL did not have a significant influence on CSS (p = 0.642). Conclusions AL had a negative influence on OS, DFS, and RFR. Whether aggressive surgical clinical management of AL has any influence on CSS remains unclear. Clinical trial registration The study was registered at ClinicalTrials.gov (NCT06059924).
30 April 2025 in Langenbeck's Archives of Surgery
Purpose The improved prognosis of rectal cancer through modern therapeutic approaches raises questions regarding quality of life (QoL) and functional outcomes. In this study, we compared post-transanal total mesorectal excision (taTME) short- and long-term QoL and functional outcomes with those after abdominal TME (abTME). Methods Prospective data from patients who underwent elective taTME or abTME for stage I-III rectal cancer followed by anastomosis were retrospectively propensity score-adjusted. The primary endpoint, QoL, was assessed with the European Organization for Research and Treatment of Cancer core questionnaire (EORTC QLQ-C30). Functional outcomes were the secondary endpoints. Results Among 494 patients during 2013–2022, 187 patients who underwent taTME and 62 patients who underwent abTME were included. QoL was worse after taTME at isolated time points: overall QoL (after 3 years: 72 vs. 82 points, p = 0.017) and QLQ-total (after 3 years: 81 vs. 87 points, p = 0.028; after 4 years: 82 vs. 89 points, p = 0.012). After propensity score matching, the between-group differences were still significant but smaller: overall QoL − 6 points, p = 0.021; QLQ-total − 5 points, p = 0.026. Conclusion The differences reported at isolated time points have questionable clinical relevance. Therefore, taTME and traditional abTME seem to have comparable long-term QoL and functional outcomes. Clinical trial registration ClinicalTrials.gov, NCT06505863, https://clinicaltrials.gov/search?id=NCT06505863.
1 November 2023 in BJS Open
4 August 2026 in Patient Safety in Surgery
Background: The association between hospital volume and outcomes after gastric cancer resection remains controversial. This Swiss national registry study investigated the association between annual hospital-volume for gastric cancer resection and short-term outcomes. Methods: This retrospective population-based study included adult patients undergoing elective gastric cancer resection in Switzerland between 2013 and 2022. Annual hospital volume was defined as the number of gastric cancer resections performed at the treating hospital in the calendar year of surgery. The primary endpoint was in-hospital mortality. Secondary endpoints were postoperative complications, failure to rescue (FTR), reoperation, and length of hospital stay (LOS). Generalized additive regression models (GAM), standardized mortality ratios (SMR), quantile regression, and trend tests were used to assess the association with hospital volume. Results: Among 3,861 gastric cancer resections, in-hospital mortality was 3.1%, complications occurred in 48.0%, and mean LOS was 17.1 days. Higher annual hospital volume was associated with lower mortality rates (odds ratio per 10 additional resections (OR): 0.769, 95% confidence interval (CI) 0.617–0.957; p = 0.019) and FTR (OR: 0.727, 95% CI: 0.581–0.910; p = 0.005), but with higher complication rates (OR: 1.104, CI: 1.027–1.185; p = 0.007). The very-high-volume quintile (22–39 resections/year) had the lowest mortality rate (1.4%), despite the highest comorbidity burden and complication rate. Gastric cancer resection volume was associated with SMR ( p < 0.001). No significant overall association between hospital volume and LOS was observed. During the study period, mortality and FTR decreased, while annual hospital volume increased. Conclusion: In this Swiss cohort, higher annual gastric cancer resection volume was associated with lower in-hospital mortality and FTR rates. The lower mortality observed in higher-volume hospitals occurred despite a greater comorbidity burden and higher recorded complication rates, suggesting that differences in the response to postoperative complications may contribute to the observed volume–outcome relationship.